Janet  Napolitano net worth and biography

Janet Napolitano Biography and Net Worth

Director of Vir Biotechnology
Ms. Janet Napolitano has served on our Board since August 2020. Ms. Napolitano served as President of the University of California from September 2013 until her departure in August 2020. Prior to her time serving as the President of the University of California, she served as the U.S. Secretary of Homeland Security from 2009 to 2013, as governor of the state of Arizona from 2003 to 2009, as attorney general of Arizona from 1998 to 2003 and as U.S. attorney for the District of Arizona from 1993 to 1997. In 2010, Ms. Napolitano was awarded the University of Virginia’s Thomas Jefferson Foundation Medal for law. In 2014, Ms. Napolitano was appointed as a tenured faculty member of the University of California Berkeley’s Goldman School of Public Policy. In 2015, Ms. Napolitano was elected to the American Academy of Arts and Sciences, and in 2017, she was inducted into the American Philosophical Association. Ms. Napolitano currently serves on the Council of the American Law Institute and is a board member of Zoom Video Communications, Inc. and the Council on Foreign Relations. Ms. Napolitano holds a B.S. in political science (summa cum laude) from Santa Clara University where she was a Truman Scholar and the university’s first female valedictorian and a J.D. from the University of Virginia School of Law.

What is Janet Napolitano's net worth?

The estimated net worth of Janet Napolitano is at least $20,112.16 as of October 9th, 2024. Ms. Napolitano owns 2,984 shares of Vir Biotechnology stock worth more than $20,112 as of November 21st. This net worth estimate does not reflect any other investments that Ms. Napolitano may own. Learn More about Janet Napolitano's net worth.

How do I contact Janet Napolitano?

The corporate mailing address for Ms. Napolitano and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Janet Napolitano's contact information.

Has Janet Napolitano been buying or selling shares of Vir Biotechnology?

Janet Napolitano has not been actively trading shares of Vir Biotechnology in the last ninety days. Most recently, Janet Napolitano sold 12,190 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $7.80, for a transaction totalling $95,082.00. Following the completion of the sale, the director now directly owns 11,616 shares of the company's stock, valued at $90,604.80. Learn More on Janet Napolitano's trading history.

Who are Vir Biotechnology's active insiders?

Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.

Are insiders buying or selling shares of Vir Biotechnology?

In the last twelve months, insiders at the sold shares 13 times. They sold a total of 172,771 shares worth more than $1,697,054.16. The most recent insider tranaction occured on November, 5th when EVP Verneuil Vanina De sold 2,347 shares worth more than $22,226.09. Insiders at Vir Biotechnology own 15.6% of the company. Learn More about insider trades at Vir Biotechnology.

Information on this page was last updated on 11/5/2024.

Janet Napolitano Insider Trading History at Vir Biotechnology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/9/2024Sell12,190$7.80$95,082.0011,616View SEC Filing Icon  
11/30/2021Sell1,435$46.25$66,368.75View SEC Filing Icon  
8/30/2021Sell1,435$51.15$73,400.254,809View SEC Filing Icon  
See Full Table

Janet Napolitano Buying and Selling Activity at Vir Biotechnology

This chart shows Janet Napolitano's buying and selling at Vir Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vir Biotechnology Company Overview

Vir Biotechnology logo
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $6.74
Low: $6.62
High: $7.03

50 Day Range

MA: $7.94
Low: $6.74
High: $10.17

2 Week Range

Now: $6.74
Low: $6.62
High: $13.09

Volume

1,473,682 shs

Average Volume

1,539,328 shs

Market Capitalization

$928.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46